Research programme: eye disorders therapy - Alcon/Origenis

Drug Profile

Research programme: eye disorders therapy - Alcon/Origenis

Alternative Names: MOREsystem®

Latest Information Update: 12 Apr 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Alcon
  • Developer Alcon; Origenis
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Eye disorders

Most Recent Events

  • 17 Oct 2008 Preclinical development is ongoing USA and Germany
  • 15 Oct 2008 Alcon Research and Origenis extend their research alliance for the treatment of eye disorders
  • 01 Dec 2005 Morphochem AG has been acquired by Biovertis AG
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top